Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 07, 2019 07:30 ET | Source: KemPharm

KemPharm Announces FDA Approval of sNDA for Two Additional Strengths of APADAZ® (4.08 mg benzhydrocodone/325 mg APAP and 8.16 mg benzhydrocodone/325 mg APAP)

APADAZ® Now Approved in Three Dosage Strengths, Providing Greater Flexibility to Prescribers Through Additional Dosing Options CORALVILLE, Iowa, Jan. 07, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc....
December 19, 2018 07:30 ET | Source: KemPharm

KemPharm Provides Corporate Update on Partnering Process for ADHD Prodrug Portfolio

CELEBRATION, Fla., Dec. 19, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today...
December 12, 2018 07:30 ET | Source: KemPharm

KemPharm Presents Poster at ACNP’s 57th Annual Meeting Highlighting the Intravenous Abuse Potential of Serdexmethylphenidate (SDX)

Findings suggest that SDX, a prodrug of d-methylphenidate, is unlikely to be attractive for intravenous abuse CELEBRATION, Fla., Dec. 12, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a...
November 13, 2018 07:30 ET | Source: KemPharm

KemPharm Enhances Pipeline with the Addition of KP879, a Potential New Treatment for Stimulant Use Disorder

KP879 is being developed with serdexmethylphenidate, KemPharm’s prodrug of d-methylphenidate, to address a critical unmet need in the treatment of problematic stimulant abuse CELEBRATION, Fla.,...
November 08, 2018 16:05 ET | Source: KemPharm

KemPharm, Inc. Reports Third Quarter 2018 Results

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Development Highlights: Announced positive topline results from KP415.E01 efficacy and safety trial...
November 01, 2018 07:30 ET | Source: KemPharm

KemPharm to Report Third Quarter 2018 Results

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, November 8, 2018, 4:30 p.m. ET CORALVILLE, Iowa, Nov. 01, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc....
October 30, 2018 16:05 ET | Source: KemPharm

KemPharm Enters Into License Agreement with KVK Tech for the Commercialization of APADAZ®

Partnership with KVK, One of the Largest Manufacturers of Controlled Substances in the U.S., Opens the Door for Commercial Launch of APADAZ with PBMs and MCOs KemPharm to Host a Conference Call...
October 24, 2018 07:30 ET | Source: KemPharm

KemPharm Presents Data from Intranasal and Intravenous Human Abuse Potential Trials of KP415 Prodrug at the American Academy of Child & Adolescent Psychiatry Meeting

CORALVILLE, Iowa, Oct. 24, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced...
October 23, 2018 07:30 ET | Source: KemPharm

KemPharm and twoXAR Announce Technology Collaboration to Develop Prodrug-Based Therapies for Multiple Indications

Drug Development Approach Combines twoXAR’s Artificial-Intelligence-Driven Drug Discovery Technology with KemPharm’s LATTM Prodrug Technology CORALVILLE, Iowa, Oct. 23, 2018 (GLOBE NEWSWIRE) --...
October 11, 2018 16:05 ET | Source: KemPharm

KemPharm Provides Highlights from KOL Investor Event Focused on the ADHD Treatment Landscape

Event Held Today, October 11, 2018 CORALVILLE, Iowa, Oct. 11, 2018 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of...